Fairmount Funds Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $49.1M | Buy |
1,772,839
+670,591
| +61% | +$18.6M | 6.36% | 8 |
|
|
2025
Q1 | $24.5M | Sell |
1,102,248
-1,092,093
| -50% | -$24.3M | 3.8% | 11 |
|
|
2024
Q4 | $43.4M | Sell |
2,194,341
-1,010,500
| -32% | -$20M | 4.32% | 11 |
|
|
2024
Q3 | $80.1M | Hold |
3,204,841
| – | – | 6.49% | 6 |
|
|
2024
Q2 | $59.8M | Hold |
3,204,841
| – | – | 6.76% | 7 |
|
|
2024
Q1 | $63.2M | Buy |
3,204,841
+321,620
| +11% | +$6.35M | 6.89% | 5 |
|
|
2023
Q4 | $50.6M | Buy |
2,883,221
+408,660
| +17% | +$7.17M | 5.34% | 6 |
|
|
2023
Q3 | $43M | Buy |
2,474,561
+1,770,102
| +251% | +$30.7M | 5.17% | 6 |
|
|
2023
Q2 | $9.92M | Buy |
+704,459
| New | +$9.92M | 1.4% | 15 |
|
|
2020
Q4 | – | Sell |
-212,746
| Closed | -$3.26M | – | 19 |
|
|
2020
Q3 | $3.26M | Buy |
212,746
+12,621
| +6% | +$193K | 1.38% | 16 |
|
|
2020
Q2 | $5.1M | Hold |
200,125
| – | – | 2.27% | 14 |
|
|
2020
Q1 | $3.1M | Buy |
200,125
+34,807
| +21% | +$539K | 1.88% | 14 |
|
|
2019
Q4 | $1.83M | Buy |
+165,318
| New | +$1.83M | 1.11% | 14 |
|